Short-term treatment for acute myelogenous leukaemia

R Bell, A Z Rohatiner, M L Slevin, J M Ford, H S Dhaliwal, G Henry, B G Birkhead, J A Amess, J S Malpas, T A Lister
1982 BMJ (Clinical Research Edition)  
Short-term treatment with doxorubicin, cytarabine, and 6-thioguanine was given to 91 consecutive adults with acute myelogenous leukaemia. Fifty patients received high doses (regimen I) and 41 very high doses (regimen II). Where possible, six treatment cycles were given (total dose of doxorubicin 450 mg/i2) regardless of the number of cycles required to achieve complete remission. No additional treatment was given. The remission rate was significantly higher with regimen I than with regimen II
more » ... 4/50 compared with 15/41, p <001), the latter, more intensive regimen being associated with a greater incidence of fatal infection (13/41 compared with 5/50, p <0-01). Duration of remission was, however, significantly longer with regimen II (p <0 05); the median has not yet been reached after a minimum follow-up of two years. Intensive short-term treatment is a feasible strategy for the treatment of acute myelogenous leukaemia. St Bartholomew's Hospital, London EC1A 7BE R BELL, FRACP, ICRF research fellow and honorary senior registrar (present address:
doi:10.1136/bmj.284.6324.1221 fatcat:m7amuhgwl5f5rm7buvjvcawjeu